Table 3.
Overview of the intraocular pressure (IOP) and number of hypotensive medications in eyes that underwent XEN45 implant surgery in different studies at month-3.
| Study | MMC | Type of Glaucoma | Baseline IOP, mm Hg | M3 IOP, mm Hg | IOP Lowering (%) | IOP Lowering, mm Hg | Mean Preoperative Medications |
Mean Postoperative Medications at M3 | Needling Rates at the End of the Study, n (%) |
|---|---|---|---|---|---|---|---|---|---|
| Reitsamer et al. [13] | 10–80 µg/mL 1 | POAG | 21.4 (3.6) * | 15.7 † | −25.0 † | N.A. | 2.7 (0.9) | 0.5 (0.9) | 83 (41.1) |
| Marcos-Parra et al. [15] | 10 µg/mL | OAG 3 | 19.1 (5.4) * | N.A. | N.A. | −6.1 (−9.9 to −0.1) ** | 2.5 (0.8) | N.A. | 13 (20.0) |
| Fea et al. [16] | 20 µg/mL | OAG 3 | 23.9 (7.6) * | 15.1 † | N.A. | N.A. | 3.0 (1.0) | 0.4 † | 79 (46.2) |
| Grover et al. [24] | 20 µg/mL 2 | Refractory OAG 3 | 25.1 (3.7) * | 16.6 (5.5) * | −32.7 † | −8.5 † | 3.5 (1.0) | 0.5 † | 21 (32.3) |
| Ibáñez-Muñoz et al. [25] | 10 µg/mL | OAG 3 | 22.8 (20.8 to 24.7) ** | 16.4 (14.3 to 18.5) ** | N.A. | N.A. | 3.4 (0.8) | N.A. | 19 (26.0) |
| Laborda-Guirao et al. [26] | 20 µg/mL | OAG 3 | 21.0 (5.2) * | 14.5 (13.6 to 15.4) ** | N.A. | −6.7 (−8.8 to −4.6) | 2.8 (2.7 to 3.0) ** | N.A. | 7 (8.8) |
| Theilig et al. [27] | 10 µg/mL | POAG | 24.5 (6.7) * | 16.8 (6.3) | N.A. | N.A. | 3.0 (1.1) * | 1.1 (1.4) * | 42 (42.0) |
| Hengerer et al. [28] | 10 µg/mL | OAG 4 | 32.2 (9.1) * | 14.6 † | N.A. | N.A. | 3.1 (1.0) * | −2.7 (1.2) ‡ | 67 (27.7) *** |
| Current study | 20–30 µg/mL 1 | OAG 3 | 27.0 (7.8) * | 12.2 (3.4) * | −40.8 (23.5) * | −14.8 (−20.1 to −9.5) ** | 2.3 (0.9) * | 0.1 (0.4) * | 3 (13.0) |
* Mean (Standard deviation); ** Mean (95% confidence interval); † Data about standard deviation was not provided; ‡ Mean reduction from baseline; *** All the needling procedures were done between week 1 and month 3; Abbreviations: MMC: Mitomycin C; IOP: Intraocular pressure; M: Month; POAG: Primary open-angle glaucoma, OAG: Open-angle glaucoma; NA: Not available. 1 MMC dose at the surgeon’s discretion (2 patients received 5-fluorouracil); 2 Sponges saturated with MMC; 3 It includes primary and secondary open-angle glaucoma; 4 Besides open-angle glaucoma patients, it included patients with uveitic glaucoma, angle closure glaucoma, and neovascular glaucoma.